Observations placeholder
Lumizyme
Identifier
019484
Type of Spiritual Experience
Number of hallucinations: 3
Background
A description of the experience
Alglucosidase alfa (Lumizyme, Myozyme, Genzyme) is an enzyme replacement therapy (ERT) orphan drug for treatment of Pompe disease (Glycogen storage disease type II), a rare lysosomal storage disorder (LSD) Chemically speaking, the drug is an analog of the enzyme that is deficient in patients affected by Pompe disease, alpha-glucosidase. It is the first drug available to treat this disease.
Common observed adverse reactions to alglucosidase alfa treatment are pneumonia, respiratory complications, infections and fever. More serious reactions reported include heart and lung failure and allergic shock. Myozyme boxes carry warnings regarding the possibility of life-threatening allergic response
On Jan, 6, 2016: 3 people reported to have side effects when taking Lumizyme. Among them, 3 people (100.00%) have Hallucination.
On Jan, 6, 2016: 3 people reported to have side effects when taking Lumizyme. Among them, 2 people (66.67%) have Death.
Time on Lumizyme when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |